Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. EKSO
EKSO logo

EKSO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Ekso Bionics Holdings Inc (EKSO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
--
1 Day change
0.08%
52 Week Range
13.500
Analysis Updated At
2026/05/01
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

EKSO is not a good buy right now for a beginner, long-term investor with $50,000-$100,000 to deploy. The stock has short-term technical strength, but the business fundamentals are weak, there is no fresh news catalyst, no supportive options activity, and no strong institutional or insider buying signal. I would not buy this name now; the better call is to avoid it and wait for a materially stronger fundamental setup.

Technical Analysis

The chart is bullish in the very short term: MACD histogram is positive and expanding, and the moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200. Price closed at 12.24, above the pivot at 11.251 and near first resistance at 12.038, with R2 at 12.524 as the next upside test. RSI_6 at 74.347 suggests the stock is already extended rather than offering a clean low-risk entry. Overall, the trend is positive, but the stock looks near resistance and not attractive for a beginner long-term purchase.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options activity is essentially absent: open interest and volume are both zero, so there is no meaningful sentiment read from the options market. That means options traders are not showing conviction here, and there is no bullish or bearish positioning signal to support a buy case.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
3

Positive Catalysts

  • The only positive catalyst is technical momentum: the stock is trading above key moving averages and the MACD is improving. It also had a positive regular-session move of 4.98% and continued strength in post-market trading, which shows near-term buyer interest. Similar-candlestick analysis also suggests a possible 10.29% move over the next month, though this is not a fundamental catalyst.

Neutral/Negative Catalysts

  • There was no news in the recent week, so there is no event-driven catalyst. Hedge funds are neutral and insiders are neutral, with no significant trading trends over the last quarter or month. Options data shows no participation. The business snapshot is weak: revenue fell 38.31% YoY in 2025/Q4, gross margin fell to 0, EPS was 0, and net income remained negative at -4.674M. Congress trading data is unavailable, so there is no political buying signal.

Financial Performance

Latest reported quarter: 2025/Q4. Revenue declined to 3.14M, down 38.31% YoY, which indicates shrinking top-line momentum. Net income was -4.674M, still negative, although the loss improved 36.95% YoY. EPS dropped to 0 and gross margin dropped to 0, both signaling poor operating quality and weak profitability. For a long-term beginner investor, these financials do not support an aggressive buy.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no visible Wall Street upgrades/downgrades or target revisions to assess. Based on the available data, the Wall Street view appears mixed-to-cautious: there is some short-term price strength, but the lack of analyst support, weak fundamentals, and no positive news flow argue against a bullish long-term consensus.

Wall Street analysts forecast EKSO stock price to rise
Analyst Rating
0
Wall Street analysts forecast EKSO stock price to rise
Buy
Hold
Sell
0
Current: 11.800
sliders
Low
0
Averages
0
High
0
0
Current: 11.800
sliders
Low
0
Averages
0
High
0
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$4 -> $6
AI Analysis
2025-11-18
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$4 -> $6
AI Analysis
2025-11-18
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Ekso Bionics to $6 from $4 and keeps a Buy rating on the shares. The company reported a solid Q3 report and announced it has initiated a strategic review of the current business, the analyst tells investors in a research note. The firm does not account for any transaction at this time. Ekso's sales recovery in Q3 implies that order delays from the prior quarter "appear to be idiosyncratic," but it remains to be seen if this trend can continue, contends H.C. Wainwright.
Lake Street
Buy
downgrade
$15
2025-07-29
Reason
Lake Street
Price Target
$15
2025-07-29
downgrade
Buy
Reason
Lake Street lowered the firm's price target on Ekso Bionics to $9.50 from $15 and keeps a Buy rating on the shares. Q2 revenue fell "well below" the firm's expectations, attributable to the company's Enterprise Health business. While the firm does not believe investors "should become overly concerned with the company's Q2 results," it recognizes improvements "may not be readily evident prior to the company requiring additional funds."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for EKSO
Unlock Now

People Also Watch